MEDIPOST Obtains Patent in Canada for its Stem Cell-based Alzheimer’s Disease Treatment Composition

MEDIPOST Obtains Patent for Commercializing High-efficiency Technology to Culture Stem Cell

MEDIPOST Obtains Patent for Core Alzheimer’s Disease Treatment Technology in Six European Countries

MEDIPOST Obtains Patent for its ‘CARTISTEM’ Production Technology’ in Six European Countries

MEDIPOST’s Alzheimer’s Disease Drug Approved by FDA for Clinical Trials

MEDIPOST Obtains Patent for Stem Cell Culture Medium Technique for Hair Loss Treatment

Significant increase in the revenue of MEDIPOST stem cell therapeutics CARTISTEM in comparison to the previous year

MEDIPOST acquires patents on the “Mesenchymal Stem Cell Culture Method” in 6 European countries

MEDIPOST acquires the Japanese patent in hair loss prevention and hair growth promoting composition

MEDIPOST acquires the patent in Mexico for ‘CARTISTEM’

MEDIPOST acquires US Patent for the ‘Mesenchymal Stem Cell Culture Method’

MEDIPOST, signs a contract with SK Bioland for an ankle joint indication